Download Powerpoint - Blood Journal

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
page
8
Document related concepts
no text concepts found
Transcript 
Bortezomib blocks Bax degradation in malignant B cells
during treatment with TRAIL
by Feng-Ting Liu, Samir G. Agrawal, John G. Gribben, Hongtao Ye, Ming-Qing Du,
Adrian C. Newland, and Li Jia
Blood
Volume 111(5):2797-2805
March 1, 2008
©2008 by American Society of Hematology
Bax protein instability.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Effect of TRAIL-induced Bax regulation.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Bortezomib-induced Bax protein accumulation in DHL-4 cells.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Prevention of Bax degradation by tBid at the mitochondrial level.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Bortezomib (Borte)-induced apoptosis and Bax activation in CLL cells.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Bortezomib-induced polyubiquitination and Bax–ubiquitin conjugation.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Proteasome inhibitor facilitates TRAIL-induced Bax activation and apoptosis.
Feng-Ting Liu et al. Blood 2008;111:2797-2805
©2008 by American Society of Hematology
Related documents